254P - THE IMPACT OF NON-AIDS SERIOUS ADVERSE EVENTS AND AIDS EVENTS IN PATIENTS WITH ADVANCED MULTI-DRUG RESISTANT HIV DISEASE
DW Cameron², ST Brown¹, J Singer*², H Sun², A Anis², T Kyriakides¹, BJ Angus³, K Swanson¹, A Babiker³, M Holodniy¹ for the OPTIMA Study Team
¹VA Cooperative Studies, USA, ²CTN, Canada, ³MRC UK

255P - VIROLOGIC EFFICACY OF ONCE-DAILY KALETRA IN AN INTRAVENOUS DRUG USER (IVDU) POPULATION ON AN ANTIRETROVIRAL DIRECTLY OBSERVED THERAPY (DOT) PROGRAM
J Grebely*¹, H Tossonian¹, J Raffa¹, L McKenzie², N Suvorova², M Viljoen², M McLean², S DeVlaming², B Conway^1
1University of British Columbia; ²PCHC, VCHA

256P - A RETROSPECTIVE REVIEW OF LIPID PROFILES AND MANAGEMENT AMONG PATIENTS RECEIVING ANTIRETROVIRALS THERAPY: ACHIEVING FRAMINGHAM TARGET LIPID LEVELS IN CLINICAL SE
Joss de Wet*¹, Kate Heath², R Voigt¹, C Murphy¹, B Willoughby¹, P Sestak^1
1Spectrum Health Vancouver, ²Epilogic consulting, Vancouver, British Columbia

257P - RELATIONSHIP OF LIPID ABNORMALITIES TO ARV REGIMENS AMONG HIV INFECTED INDIVIDUALS
JM Raboud, E Phillips, R Saskin, S Sterling, Z Abdurrahman,S Walmsley
University of Toronto, Toronto, Ontario

258P - AN EVALUATION OF THE PREVALENCE, PATTERNS, AND REASONS FOR USING COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USAGE AMONG HIV INFECTED PATIENTS
Jinell B Mah Ming¹, Kathy KY Lee*¹, Hartmut B Krentz^1,2, Michael John Gill^1,2
1Southern Alberta Clinic, ²Faculty of Medicine, University of Calgary, Calgary, Alberta

259P - MANAGING INJECTIONS FOR PATIENTS ON ENFUVIRTIDE THERAPY: A NURSING PERSPECTIVE
L Casciaro*¹, A D’Aquila¹, R Saskin¹, S Walmsley^1,2
1University Health Network, ²University of Toronto, Toronto, Ontario

260P - A PROSPECTIVE STUDY OF BODY FAT REDISTRIBUTION, LIPID AND GLUCOSE ABNORMALITIES IN HIV INFECTED PATIENTS INITIATING PROTEASE INHIBITOR BASED HAART
A Foster, R Saskin , AM Cheung, J Raboud, K Logue, G Fantas, A Assad , R Clarke, S Walmsley *
University Health Network, University of Toronto

261P - LACK OF CORRELATION OF SERUM LACTATE WITH CLINICAL SYMPTOMS IN HIV-POSITIVE INDIVIDUALS ON HAART
DHS Tan*³, J Raboud^2,3, S Walmsley^1,3
1Toronto Hospital Immunodeficiency Clinic; ²Prosserman Center for Health Research; ³University of Toronto, Toronto, Ontario

262P - METABOLIC CONSEQUENCES OF PROTEASE INHIBITOR, NUCLEOSIDE, OR NNRTI-SPARING HAART OF EQUIVALENT VIRAL AND IMMUNE POTENCY IN TREATMENT-NAIVE SUBJECTS
CL Cooper*, JB Angel, D Cote, I Seguin, RPG van Heeswijk, Y Khaliq, G Garber, DW Cameron
Division of Infectious Diseases, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario

263P - A COMPARISON OF DYSLIPIDEMIAS ASSOCIATED WITH EITHER LOPINAVIR/RITONAVIR OR INDINAVIR/RITONAVIR BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
T Antoniou*, L Park-Wyllie, E Boyle
St Michael’s Hospital, Toronto, Ontario

264P - VIROLOGIC EFFICACY AND LIPID PROFILES OF PATIENTS RECEIVING ATAZANAVIR (ATZ) WITH AND WITHOUT RITONAVIR (RTV) BOOSTING
S Jutha*, J Grebely, L Gallagher, J Raffa, J Prasad, B Conway
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia

265P - INCIDENCE OF AND RISK FACTORS FOR TENOFOVIR INDUCED NEPHROTOXICITY: A RETROSPECTIVE COHORT STUDY
T Antoniou*¹, J Raboud², S Chihrin³, D Yoong¹, K Gough¹, A Rachlis⁴, MR Loutfy^3
1St Michael’s Hospital; ²University Health Network; ³Canadian Immunodeficiency Research Collaborative Inc; ⁴Sunnybrook & Women’s College Health Sciences Centre, Toronto, Ontario

266P - PURE RED CELL APLASIA ASSOCIATED WITH DIDANOSINE (DDI) THERAPY: A NEWLY REPORTED COMPLICATION
David R Burdge^1,2, Kath Webster^1,3
1Oak Tree Clinic, Children’s and Women’s Health Centre of British Columbia, ²University of British Columbia, ³BCPWA Treatment Information Program, Vancouver, British Columbia

267P - CREATINE KINASE AS A MARKER OF TREATMENT ASSOCIATED MYOPATHY IN HIV DISEASE
CM Tsoukas*, J Falutz, J Szabo, G Hatzakis
McGill University Health Centre, Immune Deficiency Treatment Centre, Montreal, Quebec

268P - ELIGIBILITY OF HIV-HCV COINFECTED ADULTS FOR HCV TREATMENT
SD Shafran*, LD Mashinter, A Lindemulder, S Houston, G Taylor, M Joffe, S Takaya, L Saxinger, D Kunimoto, I Chiu, L Miedzinski
Division of Infectious Diseases, Department of Medicine, University of Alberta, Calgary, Alberta

269P - HEPATITIS C VIRUS (HCV) AS AN INDEPENDENT RISK FACTOR FOR ELEVATED VENOUS LACTATE LEVELS (VLL) AFTER HAART INITIATION
P Braitstein*^1,2, H Cote¹, B Yip¹, V Montessori¹, J Montaner^1,2, R Hogg^1,2
1BC Center for Excellence in HIV, ²University of British Columbia, Vancouver, British Columbia

270P - IMPACT OF LAMIVUDINE AND/OR TENOFOVIR DF TREATMENT ON LIVER ENZYMES IN HIV/HBV CO-INFECTED PATIENTS
S Chihrin*¹, J Raboud², R Saskin², D Fletcher¹, A Rachlis², C Kovacs¹, E Phillips², S Walmsley², MR Loutfy^1
1Canadian Immunodeficiency Research Collaborative; ²University of Toronto, Toronto, Ontario

271P - TREATMENT OF HCV IN HIV/HCV CO-INFECTED INMATES IN FEDERAL CORRECTIONAL INSTITUTIONS IN THE PACIFIC REGION IN BRITISH COLUMBIA
J Farley¹, G Walters¹, J Grebely^1,2, J Raffa^1,2, B Conway^1,2
1Downtown Infectious Diseases Clinic, ²Department of Pharmacology and Therapeutics, ³University of British Columbia, Vancouver, British Columbia

272P - HIV-HEPATITIS C (HCV) CO-INFECTED INDIVIDUALS FACE NUMEROUS OBSTACLES TO HEALTH
Marina B Klein*¹, Danielle Rouleau², Karina Pourreaux¹, Rosa Morales¹, Sylvie Beauchamp^2
1Immunodeficiency, Mtl Chest, McGill University Health Centre; ²UHRESS Notre-Dame, Centre Hosp Univ Mtl, Montreal, Quebec

273P - CLINICAL EFFECTIVENESS OF HCV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS AND THE UTILITY OF LIVER BIOPSY IN REAL PRACTICE
S Chihrin¹, J Raboud², R Saskin², D Fletcher¹, A Rachlis², C Kovacs¹, E Phillips², Walmsley², MR Loutfy*^1
1Canadian Immunodeficiency Research Collaborative; ²University of Toronto, Toronto, Ontario

274P - HPV-16 VIRAL LOAD IS HIGHER IN HIV+ WOMEN WITH HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS COMPARED TO THOSE WITH NORMAL CYTOLOGY SMEARS
J Lefevre*^1,2, C Hankins^3,4, D Money⁵, A Rachlis⁶, K Pourreaux⁴, The Canadian Women’s HIV Study Group, F Coutlee^1,2
1Laboratoire de Virologie Moleculaire, Centre de Recherche du Centre Hospitalier de l’Universite de Montreal; ²Departement de Microbiologie et Immunologie, Universite de Montreal; ³Joint Departments of Epidemiology, Biostatistics, and Occupational Health, and Department of Oncology, McGill University; ⁴Direction de la Sante Publique de Montreal-Centre, Institut National de la Sante Publique du Quebec; ⁵Departement de Microbiologie et Infectiologie, Centre Hospitalier de l’Universite de Montreal, Montreal, Quebec

275P - A PROTEIN BEAD ARRAY (PBA) FOR THE SIMULTANEOUS HIV-1 ANTIBODY MEASUREMENTS FROM FRESH PLASMA AND DRIED BLOOD SPOTS (DBS)
S Faucher, A Sherring, A Martel, T Ding, M Bergeron, L Malloch, J Kim, P Sandstrom, F Mandy*
National HIV and Retrovirology Laboratories, Health Canada, Ottawa, Ontario

276P - RESULTS FROM A MULTI-CENTRE CANADIAN CLINICAL TRIAL OF A RAPID HIV ANTIBODY TEST FOR USE IN POINT-OF-CARE, CLINICAL AND LABORATORY SETTINGS
Kevin Fonseca*¹, Rick Galli², and the Multi-Centre Rapid Test Research Teams
¹Provincial Laboratory of Public Health, ²BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia

277P - HIV-SPECIFIC IL-2 AND IFN-g ELISPOT RESPONSES AMONG HIV EXPOSED, UNINFECTED INDIVIDUALS
G Makedonas*¹, M Alary², C Lowndes^2,3, E Demers², NF Bernard^1
1Immune Deficiency Treatment Centre, McGill University Health Centre Research Institute, Montreal, Quebec; ²Population Health Research Unit, Centre hospitalier affilié universiatire de Québec and Laval University, Quebec, Quebec; ³PHLS Communicable Disease Surveillance Center, London, United Kingdom